Retatrutide Side Effects: What Clinical Trials Report
Published · Page updated
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
Retatrutide trials commonly report gastrointestinal adverse events, including diarrhea and nausea. Researchers also monitor altered skin sensations, blood pressure, heart rate and serious events. Frequencies depend on the study population and treatment group; “mostly mild or moderate” does not mean every event was minor. Retatrutide remains investigational and is not an FDA-approved treatment as of November 19, 2026. FDA status information
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This commercially interested, AI-assisted article is not an independent scientific review.
This article summarizes selected safety findings, rather than a complete safety inventory. Original abstracts and official disclosures were accessible; the complete phase 3 papers and their supplementary safety tables were not independently reviewed.

Which participants were actually studied?
Retatrutide activates GLP-1, GIP and glucagon receptors. Its findings should be assessed directly, rather than assuming that every result from another incretin medicine applies. These Lilly-funded studies answer different questions:
Study | Population and observation | What the available report contributes |
|---|---|---|
Phase 2 obesity trial | 338 adults; 48 weeks | Gastrointestinal tolerability and heart-rate observations during early development |
TRIUMPH-1 | 2,339 adults with obesity without diabetes; 80 weeks | Larger phase 3 experience in that population |
TRIUMPH-2 | 1,152 randomized adults with overweight or obesity and type 2 diabetes; 80 weeks | Group-specific adverse-event counts in people with diabetes |
Sources: phase 2 original abstract, TRIUMPH-1 original abstract, TRIUMPH-2 original abstract.
These are randomized totals, not automatically the denominators for every safety analysis. Eligibility criteria and monitored trial conditions also limit how confidently findings can be extended to other people or products.
What TRIUMPH-2 reported about side effects
The original TRIUMPH-2 abstract provides a useful example of why denominators matter. Its safety population included 292, 284 and 286 participants across three active treatment groups, and 287 placebo participants who received study treatment.
Selected reported event | Retatrutide groups: reported percentages | Placebo |
|---|---|---|
Diarrhea | 27%–34% | 13% |
Nausea | 14%–28% | 8% |
Hypotension | 1%–6% | Less than 1% |
Dysesthesia, an altered or unpleasant skin sensation | 4%–7% | 1% |
Ranges show the lowest and highest percentages across studied groups, not a pooled rate or confidence interval. They cannot predict an individual's experience. The table reproduces selected endpoints, not all reported harms. Original trial abstract The abstract also reported permanent treatment discontinuation due to adverse events or death in 4%–12% across the three retatrutide groups versus 5% with placebo. Seven participants died across all groups; the study investigator judged the deaths unrelated to the intervention. Those figures do not establish the cause of every individual event or the risk in other populations.
Lilly's accompanying disclosure also reported constipation in approximately 14%–17% of active groups versus 9% with placebo, and vomiting in approximately 6%–16% versus 4%. These supplementary figures come from the sponsor's release; we did not independently extract them from the full journal safety tables. September 2026 sponsor disclosure
Heart rate and skin sensations deserve separate attention
In phase 2, investigators observed heart-rate increases that varied with treatment group, peaked around week 24 and subsequently declined. This describes an observed pattern; it does not establish long-term cardiovascular safety. The same trial described gastrointestinal events as generally mild to moderate. Phase 2 report
Dysesthesia should not be folded into a generic “stomach side effects” category. TRIUMPH-2 recorded it separately. Future reports should clarify persistence, resolution and effects on daily activities, alongside incidence. A percentage alone cannot explain how disruptive an event was.
Why “mostly mild” is an incomplete safety summary
Severity, seriousness and treatment discontinuation answer different questions. Severity describes intensity; seriousness concerns consequences such as hospitalization or life-threatening events. Discontinuation tells readers whether study treatment was stopped. An adverse event occurring during treatment is not, by itself, proof that treatment caused it.
The November 8 knee osteoarthritis publication reported that serious adverse events were more common overall with retatrutide in both included trials. That finding should accompany summaries emphasizing common digestive symptoms. It does not establish that every serious event was caused by retatrutide. We accessed the publisher-indexed abstract, not its full safety tables. Original osteoarthritis publication
One included analysis used the TRIUMPH-1 knee osteoarthritis subgroup. Its participants must not be added to the full TRIUMPH-1 population as though they were an independent study sample. Our knee osteoarthritis evidence review addresses that efficacy question separately.
What remains uncertain?
Longer observation and broader populations are needed to characterize uncommon harms and persistence after stopping. Event timing, baseline illness, accompanying treatments and missing follow-up can change interpretation. Comparing percentages from separate drugs' trials cannot reliably identify the “safest” medicine.
Safety information also changes. On November 9, the FDA announced labeling changes for GLP-1 medicines concerning a potential increased risk of NAION, a rare optic nerve condition that can cause permanent vision loss. That communication does not supply a retatrutide-specific risk estimate or establish retatrutide's approval. FDA safety communication
Clinical trial findings concern the studied formulation under monitored conditions. They do not establish the identity, quality or clinical safety of a commercially sold research vial. See what research-use-only labeling means.
Frequently asked questions
Are nausea and diarrhea the only reported side effects?
No. Trials also recorded other digestive symptoms, altered sensations and blood-pressure or heart-rate findings. This article covers selected outcomes and is not an exhaustive safety reference.
Does a higher percentage prove that retatrutide caused an event?
No. Randomized comparisons help evaluate a possible treatment effect, but an individual event still needs clinical assessment. Interpretation also depends on uncertainty and the endpoint's definition.
Is retatrutide approved because phase 3 results are available?
No. A published trial and regulatory approval are different milestones. The FDA identifies retatrutide as unapproved as of this review date.
Review method and source access
Reviewed November 14, 2026. We read original PubMed abstracts for phase 2, TRIUMPH-1 and TRIUMPH-2; the publisher-indexed osteoarthritis abstract; and the official FDA pages and Lilly release. Full phase 3 manuscripts and supplements were not accessible for independent review. Sponsor disclosures are identified as such. This targeted review is not systematic; see our guide to reading a peptide study.
References
On November 19, 2026, we rechecked the four indexed abstracts, selected adverse-event figures in Lilly's disclosure, and the two FDA pages. We did not independently review the full phase 3 manuscripts, supplements or participant-level data. The GLP-1 class communication does not provide a retatrutide-specific NAION risk estimate.
